Bevacizumab in small cell lung cancer

Giandomenico Roviello^{1

2}, Navid Sobhani², Daniele Generali^{2

3}

Affiliations

¹ Unit of Medical Oncology, Department of Oncology, San Donato Hospital, Arezzo, Italy.
² Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy.
³ Unit of Molecular Therapy and Pharmacogenomic, ASST Cremona, Cremona, Italy.

Editorial

Giandomenico Roviello et al. Ann Transl Med. 2017 Sep.

. 2017 Sep;5(17):361.

doi: 10.21037/atm.2017.06.44.

Giandomenico Roviello^{1

2}, Navid Sobhani², Daniele Generali^{2

3}

¹ Unit of Medical Oncology, Department of Oncology, San Donato Hospital, Arezzo, Italy.
² Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy.
³ Unit of Molecular Therapy and Pharmacogenomic, ASST Cremona, Cremona, Italy.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial.
Tiseo M, Boni L, Ambrosio F, Camerini A, Baldini E, Cinieri S, Brighenti M, Zanelli F, Defraia E, Chiari R, Dazzi C, Tibaldi C, Turolla GM, D'Alessandro V, Zilembo N, Trolese AR, Grossi F, Riccardi F, Ardizzoni A. Tiseo M, et al. J Clin Oncol. 2017 Apr 20;35(12):1281-1287. doi: 10.1200/JCO.2016.69.4844. Epub 2017 Jan 30. J Clin Oncol. 2017. PMID: 28135143 Clinical Trial.

1. Tiseo M, Boni L, Ambrosio F, et al. Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial. J Clin Oncol 2017;35:1281-7. 10.1200/JCO.2016.69.4844 - DOI - PubMed
1. Roviello G, Bachelot T, Hudis CA, et al. The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials. Eur J Cancer 2017;75:245-58. 10.1016/j.ejca.2017.01.026 - DOI - PubMed
1. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50. 10.1056/NEJMoa061884 - DOI - PubMed
1. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-34. 10.1200/JCO.2007.14.5466 - DOI - PubMed
1. Petrioli R, Francini E, Fiaschi AI, et al. Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study. Med Oncol 2015;32:134. 10.1007/s12032-015-0587-x - DOI - PubMed